Oxford, UK – 11 November 2015. OGT, The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. This novel technology overcomes the limitations of restriction enzyme-based SNP probe approaches previously employed at BMGL for loss of heterozygosity (LOH) detection, allowing accurate array-based analysis of low-input DNA samples.
Based in Texas (US), BMGL provides the highest-quality genomic services across the US and to over 16 countries worldwide, and as part of this objective, utilise aCGH arrays containing both copy number variation (CNV) and SNP probes to identify a broad range of genetic syndromes. For BMGL, OGT’s intensity-based SNP probe technology provides a superior alternative to restriction enzyme-based approaches, which are unable to accurately analyse small amounts of DNA. The probes designed by OGT target each SNP allele, with the intensity ratio following hybridisation allowing reliable detection of LOH. To ensure robust and high-resolution LOH analysis, each probe set has undergone extensive optimisation and validation.
Vice President of Operations at BMGL, Mr. Sean Kim, commented: “We are dedicated to the rapid delivery of the most accurate genetic analyses. Through the application of OGT’s technology, we are now able to provide reliable array-based analysis of both copy number variation and loss of heterozygosity for challenging samples. We are now also looking to other areas of genetic analysis, expanding the use of this technology toward our complete portfolio.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
OGT’s SNP probe technology is a key component of its extensive range of aCGH arrays covering multiple application areas, including cancer and constitutional research. The latest product in development utilising this technology is the CytoSure® Constitutional v3 +SNP array, which provides enhanced exon-level coverage of all developmental disorders.
As a fully comprehensive approach to its genetic analysis strategy, BMGL also utilises OGT’s CytoCell FISH probes, and following a significant and successful validation programme, plans to further extend the use of these probes. Dr Mike Evans, CEO of OGT commented: “Through granting the licence, we are proud to be advancing the capabilities of such a prominent organisation as BMGL with our SNP array probe technology and CytoCell FISH probes. This presents just the first step in an ongoing relationship, and we look forward to continuing this close cooperation.”
Reinforcing collaboration toward the realisation of genomic medicine in the area of ophthalmic disorders.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read